Max M. Wattenberg

1.7k total citations
25 papers, 1.2k citations indexed

About

Max M. Wattenberg is a scholar working on Oncology, Immunology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Max M. Wattenberg has authored 25 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 21 papers in Oncology, 13 papers in Immunology and 3 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Max M. Wattenberg's work include Cancer Immunotherapy and Biomarkers (12 papers), Pancreatic and Hepatic Oncology Research (6 papers) and Immunotherapy and Immune Responses (6 papers). Max M. Wattenberg is often cited by papers focused on Cancer Immunotherapy and Biomarkers (12 papers), Pancreatic and Hepatic Oncology Research (6 papers) and Immunotherapy and Immune Responses (6 papers). Max M. Wattenberg collaborates with scholars based in United States and India. Max M. Wattenberg's co-authors include James W. Hodge, Sofia R. Gameiro, Gregory L. Beatty, Kwong Y. Tsang, Momodou L. Jammeh, Soldano Ferrone, Kim A. Reiss, Mansoor M. Ahmed, Robert H. Vonderheide and Susan M. Domchek and has published in prestigious journals such as Nature Communications, The Journal of Experimental Medicine and Journal of Clinical Oncology.

In The Last Decade

Max M. Wattenberg

24 papers receiving 1.2k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Max M. Wattenberg United States	14	843	505	251	250	240	25	1.2k
Karsten A. Pilones United States	16	1.4k 1.7×	1.1k 2.3×	342 1.4×	236 0.9×	449 1.9×	41	2.0k
Shuhua Wei China	12	443 0.5×	559 1.1×	195 0.8×	157 0.6×	347 1.4×	21	1.1k
Molykutty J. Aryankalayil United States	14	983 1.2×	810 1.6×	449 1.8×	287 1.1×	520 2.2×	30	1.8k
Wolf‐Dietrich Beecken Germany	15	426 0.5×	180 0.4×	268 1.1×	164 0.7×	356 1.5×	24	1.1k
Akihiro Hosoi Japan	16	568 0.7×	592 1.2×	158 0.6×	95 0.4×	236 1.0×	30	928
Joseph Baar United States	16	423 0.5×	539 1.1×	272 1.1×	79 0.3×	362 1.5×	32	1.2k
Zishuo I. Hu United States	11	748 0.9×	197 0.4×	378 1.5×	415 1.7×	217 0.9×	12	1.2k
Christian Idel Germany	16	466 0.6×	293 0.6×	123 0.5×	129 0.5×	265 1.1×	47	867
Edmund Poon United Kingdom	10	1.3k 1.5×	732 1.4×	457 1.8×	86 0.3×	199 0.8×	18	1.7k
Thomas R. Nirschl United States	15	1.0k 1.2×	677 1.3×	443 1.8×	118 0.5×	222 0.9×	33	1.4k

Countries citing papers authored by Max M. Wattenberg

Since Specialization

Citations

This map shows the geographic impact of Max M. Wattenberg's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Max M. Wattenberg with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Max M. Wattenberg more than expected).

Fields of papers citing papers by Max M. Wattenberg

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Max M. Wattenberg. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Max M. Wattenberg. The network helps show where Max M. Wattenberg may publish in the future.

Co-authorship network of co-authors of Max M. Wattenberg

This figure shows the co-authorship network connecting the top 25 collaborators of Max M. Wattenberg. A scholar is included among the top collaborators of Max M. Wattenberg based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Max M. Wattenberg. Max M. Wattenberg is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Wattenberg, Max M., Ignacio Garrido‐Laguna, Jesse Lee, et al.. (2024). Intratumoral Cell Neighborhoods Coordinate Outcomes in Pancreatic Ductal Adenocarcinoma. Gastroenterology. 166(6). 1114–1129. 11 indexed citations

Wattenberg, Max M., et al.. (2024). CD4 effector T cell expansion to identify objective responses to the CD40 agonist mitazalimab in combination with modified FOLFIRINOX (mFFX) as first-line therapy for metastatic pancreatic ductal adenocarcinoma (mPDAC) in the OPTIMIZE-1 study.. Journal of Clinical Oncology. 42(16_suppl). 2569–2569.

O’Hara, Mark H., Max M. Wattenberg, Ignacio Garrido‐Laguna, et al.. (2024). Abstract PR-10: Phase 1b study of maintenance soluble beta-glucan (Odetiglucan) in combination with a CD40 agonistic monoclonal antibody (CDX-1140) in patients with metastatic pancreatic adenocarcinoma that had not progressed on first-line chemotherapy. Cancer Research. 84(17_Supplement_2). PR–10. 1 indexed citations

Stone, Meredith L., Jesse Lee, Jae W. Lee, et al.. (2024). Hepatocytes coordinate immune evasion in cancer via release of serum amyloid A proteins. Nature Immunology. 25(5). 755–763. 23 indexed citations

Wattenberg, Max M., Yago Pico de Coaña, Malin Carlsson, et al.. (2024). Abstract C038: Interim pharmacodynamic analyses of mitazalimab in combination with FOLFIRINOX in first-line metastatic pancreatic ductal adenocarcinoma (mPDAC) identify CD4 effector T cells as a correlate of treatment outcomes. Cancer Research. 84(2_Supplement). C038–C038. 1 indexed citations

Thomas, Stacy K., Max M. Wattenberg, Mark Uhlik, et al.. (2023). Kupffer cells prevent pancreatic ductal adenocarcinoma metastasis to the liver in mice. Nature Communications. 14(1). 6330–6330. 20 indexed citations

O’Hara, Mark H., Max M. Wattenberg, Ignacio Garrido‐Laguna, et al.. (2023). A phase 1b, open-label, two-part safety, tolerability, and efficacy study of a soluble beta-glucan (odetiglucan) in combination with a CD40 agonistic monoclonal antibody (CDX-1140) in patients with metastatic pancreatic adenocarcinoma whose disease did not progress during first-line (1L) chemotherapy.. Journal of Clinical Oncology. 41(16_suppl). TPS4201–TPS4201. 1 indexed citations

Wattenberg, Max M., Kathleen Graham, Meredith L. Stone, et al.. (2023). Cancer immunotherapy via synergistic coactivation of myeloid receptors CD40 and Dectin-1. Science Immunology. 8(89). eadj5097–eadj5097. 33 indexed citations

Wattenberg, Max M., et al.. (2021). Systemic inflammation is a determinant of outcomes of CD40 agonist–based therapy in pancreatic cancer patients. JCI Insight. 6(5). 24 indexed citations

10.

Lin, Jeffrey H., Austin P. Huffman, Max M. Wattenberg, et al.. (2020). Type 1 conventional dendritic cells are systemically dysregulated early in pancreatic carcinogenesis. The Journal of Experimental Medicine. 217(8). 127 indexed citations

11.

Reiss, Kim A., Max M. Wattenberg, Nevena Damjanov, et al.. (2020). A Pilot Study of Galunisertib plus Stereotactic Body Radiotherapy in Patients with Advanced Hepatocellular Carcinoma. Molecular Cancer Therapeutics. 20(2). 389–397. 11 indexed citations

12.

Wattenberg, Max M. & Gregory L. Beatty. (2020). Overcoming immunotherapeutic resistance by targeting the cancer inflammation cycle. Seminars in Cancer Biology. 65. 38–50. 40 indexed citations

13.

Wattenberg, Max M., Shun Yu, Peter J. O’Dwyer, et al.. (2019). Platinum response characteristics of patients with pancreatic ductal adenocarcinoma and a germline BRCA1, BRCA2 or PALB2 mutation. British Journal of Cancer. 122(3). 333–339. 130 indexed citations

14.

Wattenberg, Max M., Lawrence Fong, Ravi A. Madan, & James L. Gulley. (2016). Immunotherapy in genitourinary malignancies. Current Opinion in Urology. 26(6). 501–507. 6 indexed citations

15.

Bernstein, M., Charlie Garnett‐Benson, Anna Velcich, et al.. (2014). Radiation-Induced Modulation of Costimulatory and Coinhibitory T-Cell Signaling Molecules on Human Prostate Carcinoma Cells Promotes Productive Antitumor Immune Interactions. Cancer Biotherapy and Radiopharmaceuticals. 29(4). 153–161. 69 indexed citations

16.

Wattenberg, Max M., et al.. (2014). Unlocking the Combination: Potentiation of Radiation-Induced Antitumor Responses with Immunotherapy. Radiation Research. 182(2). 126–138. 58 indexed citations

17.

Wattenberg, Max M., Anna Kwilas, Sofia R. Gameiro, Adam P. Dicker, & James W. Hodge. (2014). Expanding the use of monoclonal antibody therapy of cancer by using ionising radiation to upregulate antibody targets. British Journal of Cancer. 110(6). 1472–1480. 22 indexed citations

18.

Kanagavelu, Saravana, Seema Gupta, Xiaodong Wu, et al.. (2014). In VivoEffects of Lattice Radiation Therapy on Local and Distant Lung Cancer: Potential Role of Immunomodulation. Radiation Research. 182(2). 149–162. 108 indexed citations

19.

Henson, Adrianna, Joseph B. Moore, Pascale Alard, et al.. (2013). Mitochondrial function is impaired in yeast and human cellular models of Shwachman Diamond syndrome. Biochemical and Biophysical Research Communications. 437(1). 29–34. 15 indexed citations

20.

Henson, Adrianna, Sharon Singh, Max M. Wattenberg, et al.. (2012). Impaired growth, hematopoietic colony formation, and ribosome maturation in human cells depleted of Shwachman–Diamond syndrome protein SBDS. Pediatric Blood & Cancer. 60(2). 281–286. 12 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact